192 related articles for article (PubMed ID: 21997136)
1. An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Yashiro M; Qiu H; Hasegawa T; Zhang X; Matsuzaki T; Hirakawa K
Br J Cancer; 2011 Nov; 105(10):1522-32. PubMed ID: 21997136
[TBL] [Abstract][Full Text] [Related]
2. A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Qiu H; Yashiro M; Zhang X; Miwa A; Hirakawa K
Cancer Lett; 2011 Aug; 307(1):47-52. PubMed ID: 21482024
[TBL] [Abstract][Full Text] [Related]
3. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Yashiro M; Nishii T; Hasegawa T; Matsuzaki T; Morisaki T; Fukuoka T; Hirakawa K
Br J Cancer; 2013 Nov; 109(10):2619-28. PubMed ID: 24129235
[TBL] [Abstract][Full Text] [Related]
4. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Zhang X; Yashiro M; Ren J; Hirakawa K
Oncol Rep; 2006 Sep; 16(3):563-8. PubMed ID: 16865256
[TBL] [Abstract][Full Text] [Related]
6. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Xu JM; Li YM; Wang Y; Zhao CH; Yuan SJ; Yang WW; Li ZQ; Han Y; Azzariti A; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):578-82. PubMed ID: 17236550
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
9. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Kishida O; Miyazaki Y; Murayama Y; Ogasa M; Miyazaki T; Yamamoto T; Watabe K; Tsutsui S; Kiyohara T; Shimomura I; Shinomura Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):584-94. PubMed ID: 15723219
[TBL] [Abstract][Full Text] [Related]
12. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
[TBL] [Abstract][Full Text] [Related]
14. DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells.
Qiu H; Yashiro M; Shinto O; Matsuzaki T; Hirakawa K
Cancer Sci; 2009 Jan; 100(1):181-8. PubMed ID: 19037991
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
16. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
17. Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma.
Zhang X; Yashiro M; Ohira M; Ren J; Hirakawa K
Cancer Sci; 2006 Sep; 97(9):938-44. PubMed ID: 16805821
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
[TBL] [Abstract][Full Text] [Related]
19. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Kim HP; Han SW; Kim SH; Im SA; Oh DY; Bang YJ; Kim TY
Mol Cancer Ther; 2008 Mar; 7(3):607-15. PubMed ID: 18347147
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
